Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Establishment and characterization of a novel MYC/BCL2 “double-hit” diffuse large B cell lymphoma cell line, RC

Fig. 6

Effects of an ATP competitive mTOR inhibitor AZD8055 in RC cells. a Cells from RC and three additional representative DLBCL cell lines (MZ, LP, and BJAB) were treated with increasing concentrations of AZD8055. Cell viability was assessed by the CellTiter-Glo Luminescent Assay after 72 h of treatment. Graph shows data that is representative of two independent experiments with triplicate wells for each drug concentration. b RC cells were treated with the indicated AZD9055 concentrations for 24 h. MZ cells were used as a negative control. RC cells treated with the AKT inhibitor MK-2206 were also used as a control. Cell extracts were purified and immunoblot for p-AKT, AKT, and p-mTOR. Actin was used a loading control

Back to article page